Balanced news tone
News Sentiment
TNXP sentiment intelligence
Tonix Pharmaceuticals Holding Corp news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
News tone and price action are not far from neutral.
81/100 classification confidence.
directly relevant articles
high-authority source matches
-0.8% over one week, +3.5% over four weeks, trend inactive, and below fair value.
Total debt per share of Tonix Pharmaceuticals Holding Corp. – GETTEX:TPM0
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Tonix Pharmaceuticals director Stillwell buys $58,250 in shares
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Jun 2026 07:00
- Source
- Investing.com
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
Fibromyalgia and Lyme biotech Tonix lines up two May investor talks
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 May 2026 07:00
- Source
- Stock Titan
Tonix Pharmaceuticals Holding (TNXP) Q1 Loss Deepens To US$40.2 Million Reinforcing Bearish Narratives
- Tone
- Negative 18/100
- Event
- Market update
- Published
- 12 May 2026 07:00
- Source
- simplywall.st
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
Tonix Pharmaceuticals (NASDAQ: TNXP) shareholders back reverse split authority and new 2026 stock incentive plan
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 07 May 2026 07:00
- Source
- Stock Titan
35 million insured Americans gain access to Tonix fibromyalgia drug
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 06 May 2026 07:00
- Source
- Stock Titan
Tonix Pharmaceuticals (TNXP) Proxy filing Summary
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 Apr 2026 23:07
- Source
- Quartr
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
No U.S. Lyme preventive exists; Tonix tests 4-month single dose
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 31 Mar 2026 07:00
- Source
- Stock Titan
Tonix Pharmaceuticals (NASDAQ: TNXP) puts reverse split and 2026 equity plan to vote
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 30 Mar 2026 07:00
- Source
- Stock Titan
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Mar 2026 07:00
- Source
- TradingView
Lyme disease and mpox studies put Tonix on vaccine congress agenda
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 23 Mar 2026 07:00
- Source
- Stock Titan
Auditor change at Tonix (NASDAQ: TNXP) after going concern warning
- Tone
- Negative 18/100
- Event
- Balance sheet
- Published
- 18 Mar 2026 07:00
- Source
- Stock Titan
Will Tonix Pharmaceuticals Holding (NASDAQ:TNXP) Spend Its Cash Wisely?
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 01 Dec 2025 08:00
- Source
- simplywall.st
Tonix Pharmaceuticals Stock Jumps Into Retail Spotlight After $25M Buyback Boost — Traders See ‘Blueprint For Rerating’
- Tone
- Neutral 50/100
- Event
- Capital return
- Published
- 18 Nov 2025 08:00
- Source
- Stocktwits
Tonix Pharmaceuticals Announces U.S. Commercial Availability of TONMYA™ (cyclobenzaprine HCl sublingual tablets) as a First-in-Class Fibromyalgia Treatment
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Nov 2025 08:00
- Source
- Market source
Tonix Pharma Scores Best Day Since March On Hopes For First New Fibromyalgia Drug Approval in 16 Years; Retail’s Optimistic
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 13 Aug 2025 01:31
- Source
- Stocktwits